Literature DB >> 23001040

The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

S N Malek1.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional chemotherapy treatment approaches. CLL as a disease entity is defined by a relatively parsimonious set of diagnostic criteria and therefore likely constitutes an umbrella term for multiple related illnesses. Of the enduring fundamental biological processes that affect the biology and clinical behavior of CLL, few are as central to the pathogenesis of CLL as recurrent acquired genomic copy number aberrations (aCNA) and recurrent gene mutations. Here, a state-of-the-art overview of the pathological anatomy of the CLL genome is presented, including detailed descriptions of the anatomy of aCNA and gene mutations. Data from SNP array profiling and large-scale sequencing of large CLL cohorts, as well as stimulated karyotyping, are discussed. This review is organized by discussions of the anatomy, underlying pathomechanisms and clinical significance of individual genomic lesions and recurrent gene mutations. Finally, gaps in knowledge regarding the biological and clinical effects of recurrent genomic aberrations or gene mutations on CLL are outlined to provide critical stimuli for future research.

Entities:  

Mesh:

Year:  2012        PMID: 23001040      PMCID: PMC3676480          DOI: 10.1038/onc.2012.411

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  123 in total

1.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

4.  Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Authors:  Elizabeth S Raveche; Erica Salerno; Brian J Scaglione; Vijaya Manohar; Fatima Abbasi; Yi-Chu Lin; Torgny Fredrickson; Pablo Landgraf; Sumant Ramachandra; Konrad Huppi; Jorge R Toro; Vincent E Zenger; Robert A Metcalf; Gerald E Marti
Journal:  Blood       Date:  2007-03-09       Impact factor: 22.113

5.  Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Authors:  Andrew R Pettitt; Richard Jackson; Stacey Carruthers; James Dodd; Susanna Dodd; Melanie Oates; Gillian G Johnson; Anna Schuh; Estella Matutes; Claire E Dearden; Daniel Catovsky; John A Radford; Adrian Bloor; George A Follows; Stephen Devereux; Anton Kruger; Julie Blundell; Samir Agrawal; David Allsup; Stephen Proctor; Earnest Heartin; David Oscier; Terry J Hamblin; Andrew Rawstron; Peter Hillmen
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

6.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

7.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

8.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Laura Z Rassenti; Angelo Veronese; Cristian Taccioli; Stefan Costinean; Baltazar D Aguda; Stefano Volinia; Manuela Ferracin; Jeff Palatini; Veronica Balatti; Hansjuerg Alder; Massimo Negrini; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

9.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

10.  Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: evidence for a role of an adjacent locus.

Authors:  Y Liu; L Szekely; D Grandér; S Söderhäll; G Juliusson; G Gahrton; S Linder; S Einhorn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

View more
  18 in total

Review 1.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Authors:  Romain Guièze; Catherine J Wu
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 2.  Genome-wide analysis of microRNA and mRNA expression signatures in cancer.

Authors:  Ming-hui Li; Sheng-bo Fu; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2015-08-24       Impact factor: 6.150

3.  Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?

Authors:  Reem Alsolami; Samantha Jl Knight; Anna Schuh
Journal:  Per Med       Date:  2013-06-01       Impact factor: 2.512

4.  Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Kamlai Saiya-Cork; Erlene Seymour; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 5.  Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.

Authors:  Gregory Lazarian; Romain Guièze; Catherine J Wu
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

6.  Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.

Authors:  Nisar A Amin; Sriram Balasubramanian; Kamlai Saiya-Cork; Kerby Shedden; Nan Hu; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-08-17       Impact factor: 12.531

7.  A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.

Authors:  Nisar A Amin; Erlene Seymour; Kamlai Saiya-Cork; Brian Parkin; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

8.  Expression and regulation of CacyBP/SIP in chronic lymphocytic leukemia cell balances of cell proliferation with apoptosis.

Authors:  Chunling Fu; Yan Wan; Hengliang Shi; Yanqing Gong; Qingyun Wu; Yao Yao; Mingshan Niu; Zhenyu Li; Kailin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-25       Impact factor: 4.553

9.  Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Jianming Pei; Valentin Robu; Madelyn Feder; Mitchell Cheung; Erin Neumann-Domer; Jacqueline Talarchek; Essel Dulaimi; Michael M Millenson; Joseph R Testa
Journal:  Cancer Genet       Date:  2014-02-15

Review 10.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.